Indiana Hemophilia & Thrombosis Center Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2001
NCT00157105
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Indiana Hemophilia &Thrombosis Center, Inc.

Active Ingredients

Drugs in Phase 4 Trials (2)

emicizumab (Hemlibra) (2 trials)

metformin (glucophage) (1 trial)

Drugs in Phase 3 Trials (1)

plasminogen (Ryplazim) (2 trials)

Drugs in Other Trials (1)

antihemophilic factor viii (Recombinant) (Adynovate) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coagulation Protein Disorders (Phase 3)

Hemophilia A (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 4